- Home
- AGIO vs GOF Comparison
AGIO vs GOF Comparison
Compare AGIO & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGIO | GOF |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2013 | 2006 |
Fundamental Metrics
Financial Performance| Metric | AGIO | GOF |
|---|---|---|
| Price | $32.48 | $8.58 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $46.25 | N/A |
| AVG Volume (30 Days) | 686.1K | ★ 2.6M |
| Earning Date | 10-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,011,000.00 | N/A |
| Revenue This Year | $237.78 | N/A |
| Revenue Next Year | $92.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.24 | $8.40 |
| 52 Week High | $46.00 | $15.09 |
Technical Indicators
Market Signals| Indicator | AGIO | GOF |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 27.33 |
| Support Level | $32.17 | N/A |
| Resistance Level | $35.77 | $10.74 |
| Average True Range (ATR) | 1.18 | 0.14 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 51.25 | 17.25 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The Fund's investment objective is to maximize total return through a combination of current income and capital appreciation. It has single operating segment. Its products are Mutual Funds, Wealth Management SMAS, Institutional SMAS, ETFS, UITS, UCITS, CIT, Closed-End Funds, Private Funds, Rydex Funds, and Variable Insurance funds.